Immunotherapy for alzheimer’s disease: DNA- and protein-based epitope vaccines

Methods in Molecular Biology

Volumn 1143, Issue , 2014, Pages 259-281

  Davtyan, Hayk ^a   Petrushina, Irina ^a   Ghochikyan, Anahit ^a  

^a NONE

Author keywords

Alzheimer s disease; Antibody; Brain pathology; ELISA; ELISPOT; Epitope vaccine; Immunohistochemistry

Indexed keywords

ALZHEIMER DISEASE VACCINE; EPITOPE; PLASMID DNA; DNA VACCINE; SUBUNIT VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; GENE GUN IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; CELLULAR IMMUNITY; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; PROCEDURES; VACCINATION;

ALZHEIMER DISEASE; ANIMALS; EPITOPES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 84907984495     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0410-5_16     Document Type: Article

References (39)

1. Price DL, Sisodia SS (1994) Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med 45:435-446
2. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6:487-498
3. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
4. Schenk DJ, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177
5. Morgan D, Diamond DM, Gottschall PE et al (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985
6. Bard F, Cannon C, Barbour R (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919
7. DeMattos RB, Bales KR, Cummins DJ (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98:8850-8855
8. Dodart JC, Bales KR, Gannon KS et al (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5:452-457
9. Nicoll JA, Wilkinson D, Holmes C et al (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-452
10. Ferrer I, Rovira MB, Guerra MLS et al (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14:11-20
11. Masliah E, Hansen L, Adame A et al (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131
12. Nicoll JA, Barton E, Boche D et al (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65:1040-1048
13. Patton RL, Kalback WM, Esh CL (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169:1048-1063
14. Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223
15. Gilman S, Koller M, Black RS et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553-1562
16. Bayer AJ, Bullock R, Jones RW et al (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64:94-101
17. Cribbs DH, Ghochikyan A, Tran M et al (2003) Adjuvant-dependent modulation ofTh1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15:505-514
18. Bard F, Barbour R, Cannon C et al (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 100:2023-2028
19. Lee M, Bard F, Johnson-Wood K (2005) Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 58:430-435
20. McLaurin J, Cecal R, Kierstead ME et al (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloidbeta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263-1269
21. Town T, Tan J, Sansone N et al (2001) Characterization of murine immunoglobulin G antibodies against human amyloid-b 1-42. Neurosci Lett 307:101-104
22. Dickey CA, Morgan DG, Kudchodkar S et al (2001) Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA Cell Biol 20(11):723-729
23. Lemere CA, Maron R, Selkoe DJ et al (2001) Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20:705-711
24. Lemere CA, Maron R, Spooner ET et al (2000) Nasal Aß treatment induces anti-Aß antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 920:328-331
25. Monsonego A, Zota V, Karni A (2003) Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112(3):415-422
26. Sigurdsson EM, Knudsen E, Asuni A et al (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloidbeta derivatives. J Neurosci 24:6277-6282
27. Singh H, Raghava GP (2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics 17:1236-1237
28. Singh H, Raghava GP (2003) ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 19:1009-1014
29. Das P, Chapoval S, Howard V et al (2003) Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies. Neurobiol Aging 24:969-996
30. Petrushina I, Ghochikyan A, Mktrichyan M et al (2007) Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/ oligomeric A{beta} species in amyloid precursor protein transgenic mice. J Neurosci 27:12721-12731
31. Movsesyan N, Ghochikyan A, Mkrtichyan M et al (2008) Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLos One 3:e21
32. Ghochikyan A, Davtyan H, Petrushina I et al (2013) Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother 9:1002-1010
33. Davtyan H, Ghochikyan A, Petrushina I et al (2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci 33:4923-4934
34. Evans CF, Davtyan H, Petrushina I et al (2013) Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimer’s Dement. [Epub ahead of print]
35. Alexander J, del Guercio MF, Maewal A (2000) Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 164:1625-1633
36. Ghochikyan A (2009) Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets 8:128-143
37. Babiuk LA, Pontarollo R, Babiuk S et al (2003) Induction of immune responses by DNA vaccines in large animals. Vaccine 21:649-658
38. Gregersen JP (2001) DNA vaccines. Naturwissenschaften 88:504-513
39. Cribbs DH, Agadjanyan MG (2005) Immunotherapy for Alzheimer's disease: potential problems and possible solutions. Curr Immunol Rev 1:139-155